Immatics Announces Third Quarter 2023 Financial Results and Business Update
14 nov. 2023 07h00 HE
|
https://immatics.com/
ACTengine® IMA203 GEN1 TCR-T targeting PRAME showed 50% (6/12) confirmed ORR in melanoma patients with median duration of response (mDOR) not reached at median follow-up of 14.4 months including...
LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations
13 nov. 2023 08h30 HE
|
Lixte Biotechnology Holdings, Inc.
PASADENA, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new...
Turnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
09 nov. 2023 21h49 HE
|
Turnstone Biologics Corp.
Turnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
Intrommune Therapeutics Presents Positive Results of Phase 1 OMEGA Study Investigating the Safety of INT301 Toothpaste for the Treatment of Peanut Allergy
09 nov. 2023 11h01 HE
|
Intrommune Therapeutics
Intrommune Therapeutics Presents Positive Results of Phase 1 OMEGA Study Investigating the Safety of INT301 Toothpaste for the Treatment Peanut Allergy
Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial
08 nov. 2023 07h00 HE
|
https://immatics.com/
Company to host conference call and webcast today, November 8, at 8:30 am EST/2:30 pm CET IMA203 data with focus on melanoma patients presented at the International Congress of the Society for...
November is Pancreatic Cancer Awareness Month
08 nov. 2023 04h00 HE
|
EnGeneIC
SYDNEY, Australia and NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Pancreatic ductal adenocarcinoma (PDAC), which accounts for >90% of pancreatic tumors, is one of the most lethal malignancies and...
The Global Market for Bispecific Antibody Therapeutics Contract Manufacturing 2023-2030: Driven by Demand for Innovative Therapies and Promising Results Seen in Clinical Development
06 nov. 2023 09h04 HE
|
Research and Markets
Dublin, Nov. 06, 2023 (GLOBE NEWSWIRE) -- The "Global Bispecific Antibody Therapeutics Contract Manufacturing Market 2023-2030" report has been added to ResearchAndMarkets.com's offering. The...
China Bispecific Antibodies Market and Clinical Pipeline Insight Report 2023-2028: Akeso are Leading the Way and Gaining Global Recognition for their Innovative Clinical Candidates
06 nov. 2023 04h23 HE
|
Research and Markets
Dublin, Nov. 06, 2023 (GLOBE NEWSWIRE) -- The "China Bispecific Antibodies Market and Clinical Pipeline Insight 2028" drug pipelines has been added to ResearchAndMarkets.com's offering. The...
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
03 nov. 2023 06h00 HE
|
Turnstone Biologics Corp.
Posters showcase Turnstone’s novel Selected TIL programs which are designed to selectively expand the most potent tumor-reactive T cells for solid tumors.
Global CD3 Antibodies Market 2023-2028: New-Generation CD3 Antibodies Targeting Diverse Indications Gain Ground
02 nov. 2023 07h43 HE
|
Research and Markets
Dublin, Nov. 02, 2023 (GLOBE NEWSWIRE) -- The "Global CD3 Antibodies Market, Dosage, Price, Sales & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering. ...